On the stock market since 2022, it operates in the world of health and science. It has 13,500 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Revenue is spread across several lines; no single product carries the company.
Average growth of 8% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades 23% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 11% a year on average.
The company sells $5.1B a year; the problem isn’t sales — it’s costs running above that number.
Over the last 12 months, company executives reported 53 buys and 31 sells. Management buying with its own money is usually read as a good sign.
A loss of $360M against $5.1B in annual sales.
At the current pace of spending, the cash lasts about 1.1 years. After that, the company needs to find new money.
On our five-subject report card, BLCO sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: BLCO has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.